DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Seckel syndrome 7 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSeckel syndrome 7 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for seckel syndrome 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Seckel syndrome is a rare autosomal recessive disorder with an estimated incidence of 1 in 10,000, first defined in 1959. It is characterised by proportionate dwarfism of prenatal onset, severe microcephaly, a bird-headed facial appearance (beaked nose, receding forehead, prominent eyes, micrognathia), and intellectual disability. Additional abnormalities have been described in the cardiovascular, haematopoietic, endocrine, gastrointestinal and central nervous systems. Patients usually have poor psychomotor development. The syndrome is genetically heterogeneous: by 2023, forty cases had been reported due to mutations in the ATR, TRAIP, RBBP8, NSMCE2, NIN, CENPJ, DNA2, CEP152 and CEP63 genes. A 2023 report of a consanguineous Pakistani family identified a novel bi-allelic missense variant in the RTTN gene (NM_173630.4: c.57G>T, p.Glu19Asp) in two siblings with severe microcephaly, severe intellectual disability, short stature, absence of speech, pointed nose, narrow face and bilateral cataract. That study expanded the known phenotype spectrum but involved only two affected individuals.
Diagnostic criteria remain uncertain. A 1982 review of the literature found that of some 60 patients published as having Seckel syndrome, only one third met the criteria originally proposed by Seckel. The author concluded that the “syndrome” is a heterogeneous group of microcephalic primordial dwarfism. A 2003 case report described a boy with Seckel syndrome and a severe atrioventricular canal defect; his parents were non-consanguineous, but autosomal recessive inheritance was still suggested. A 2017 case report of a nine-year-old child reiterated the classic features and noted that abnormalities have been described across multiple organ systems, but provided no new genetic or therapeutic data.
One therapeutic intervention has been reported in the context of haematological complications. In 2014, a six-year-old boy with Seckel syndrome and aplastic anaemia underwent allogeneic bone marrow transplantation from a ten-of-ten HLA matched unrelated donor. As of day +771, he was in good health with no further complications. The authors concluded that bone marrow transplantation is an acceptable option for Seckel syndrome complicated by haematological alterations. This is a single case, not a controlled trial.
What is still missing: no drug therapy has been tested or proposed for the core features of Seckel syndrome. There are no clinical trials, no repurposing candidates, and no evidence that any pharmacological agent modifies growth, microcephaly, or intellectual disability. The genetic heterogeneity means that any future approach would require patient stratification by causative gene. Funding for natural history studies and for preclinical work on the relevant DNA-damage response and centriole biogenesis pathways is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1982 · 202 citations
Studies of microcephalic primordial dwarfism I: Approach to a delineation of the seckel syndrome
AbstractAbstract The literature dealing with the Seckel syndrome is discussed critically. Some 60 patients have been published as having the Seckel syndrome. The diagnostic criteria proposed by Seckel are met by only 1/3 of these. It seems evident that this “syndrome” is a heterogeneous group of microcephalic primordial dwarfism. An approach to the delineation of the Seckel syndrome is given.
Seckel syndrome associated with atrioventricular canal defect: a case report
AbstractSeckel syndrome is a rare autosomal recessive disorder and its characteristic features are marked growth and mental retardation, significant microcephaly and a convex nose. We report a boy with this syndrome who also had severe cardiac anomalies. Although his parents were non-consanguineous, it is suggested that he had autosomal recessive inheritance.
Microcephaly, Short Stature, Intellectual Disability, Speech Absence and Cataract Are Associated with Novel Bi-Allelic Missense Variant in RTTN Gene: A Seckel Syndrome Case Report
AbstractThe RTTN gene encodes centriole biogenesis, replication, symmetry and cohesion, basal body organization and has recently been associated with the appearance of microcephaly syndromes. RTTN-related neurological defects including microcephaly, intellectual disability, congenital dwarfism, ophthalmic manifestations, and epilepsy are mainly due to abnormal brain development pathways and loss-of-function protein mutations. We present a consanguineous Pakistani family clinically suspected of Seckel syndrome with severe microcephaly, severe intellectual disability, short stature, absence of speech, pointed nose, narrow face and bilateral cataract in two siblings residing in the suburbs of Islamabad. Forty cases of Seckel syndrome have been reported to date in the literature due to mutations in the ATR, TRAIP, RBBP8, NSMCE2, NIN, CENPJ, DNA2, CEP152 and CEP63 genes. The objective of the study was to perform a clinical diagnosis, genetic analysis, and pathophysiology of Seckel syndrome in the proband. Whole-exome sequencing discovered NM_173630.4: c.57G > T(pGlu19Asp) missense variant in exon 2 of the RTTN gene that co-segregates in the family. This novel variant, to the best of our knowledge, is pathogenic and with autosomal recessive inheritance expressed as Seckel syndrome in the affected members of the family. The present study has expanded the genetic knowledge of novel RTTN gene variants associated with Seckel syndrome and has broadened its phenotype spectrum in the Pakistani population, which comprises diverse ethnicities. We hope that our study will open new horizons for individual molecular diagnosis and therapeutics to improve the life of patients with this congenital syndrome.
Pigmentary Changes and Atopic Dermatitis in a Patient with Seckel Syndrome
AbstractSeckel syndrome is a very rare form of primordial dwarfism characterized by antenatal and postnatal growth delay, proportionate extreme short stature, a prominent beak-like nose, hypoplasia of the malar area, small chin, microcephaly, deformed ears lacking lobules, skeletal malformations, mental retardation, and developmental delay. This syndrome has been described with associated disorders of orthopedic, neurologic, hematologic, cardiac, and ocular systems; however, only a few reports mention dermatologic involvement. We describe a 5-year-old girl with classic Seckel syndrome who presented with moderately severe atopic dermatitis and diffuse hypopigmented macules and papules.
Successful outcome of allogeneic stem cell transplantation in Seckel syndrome
AbstractSeckel syndrome is a rare autosomal recessive disease, genetically heterogeneous, characterized by short stature, prenatal microcephaly, intellectual disability, dysmorphic features, chromosomal instability, and hematological disorders. We report the case of a six-yr-old boy with Seckel syndrome and aplastic anemia who underwent successful allogeneic bone marrow transplantation from ten of ten HLA matched unrelated donor. Currently the patient is on D+771, in good health conditions and with no further complications. In conclusion, this case indicates that bone marrow transplantation is an acceptable therapeutic option for Seckel syndrome complicated by hematological alterations.
[Analysis of clinical feature and genetic mutation in a Chinese family affected with Seckel syndrome].
AbstractOBJECTIVE: To explore the clinical characteristics and genetic mutation in a family affected with Seckel syndrome. METHODS: Clinical data of the proband and his family members were collected. Potential mutations were detected by high-throughput sequencing and Sanger sequencing. RESULTS: The proband, a 7-year-and-3-month-old boy, has featured proportioned dwarfism, microcephaly, "bird head" appearance (narrow and backward forehead, prominent and protruded eyes, beak-shaped nose and microretrognathia), high-arched palate, enamel dysplasia, hypodontia, and mental retardation. His parents and two sisters were all phenotypically normal. The proband was found to harbor compound heterozygous c.1535T>A (p.L512X) and c.3346-5T>C (splicing) mutations of the CEP152 gene, which were respectively inherited from his mother and father. CONCLUSION: The clinical features and genetic mutation of a case with Seckel syndrome were delineated. The newly discovered mutations have expanded the spectrum of CEP152 gene mutations.
International Journal of Health Sciences and Pharmacy · 2017 · 1 citations · open access
Seckel Syndrome in a 9 Year Old Child
AbstractSeckel Syndrome first defined by Seckel in 1959, is a rare (incidence 1:10000) genetically heterogeneous, autosomal recessive disorder presenting at birth. This syndrome is characterised by a proportionate dwarfism of prenatal onset, severe microcephaly with a bird headed appearance (beaked nose, receding forehead, prominent eyes and micrognathia) and mental retardation in addition to the characteristics craniofacial dysmorphism and skeletal defects, abnormalities have been described in the cardiovascular hematopoietic, endocrine, gastrointestinal and central nervous system. Usually such patients have poor psychomotor development.
Zenodo (CERN European Organization for Nuclear Research) · 2017 · 1 citations · open access
Seckel Syndrome In A 9 Year Old Child
AbstractSeckel Syndrome first defined by Seckel in 1959, is a rare (incidence 1:10000) genetically heterogeneous, autosomal recessive disorder presenting at birth. This syndrome is characterised by a proportionate dwarfism of prenatal onset, severe microcephaly with a bird headed appearance (beaked nose, receding forehead, prominent eyes and micrognathia) and mental retardation in addition to the characteristics craniofacial dysmorphism and skeletal defects, abnormalities have been described in the cardiovascular hematopoietic, endocrine, gastrointestinal and central nervous system. Usually such patients have poor psychomotor development.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
